For most of the 20th century, doctors treated cancer by hitting it with everything they had. Radical surgery, high-dose radiation, brutal chemotherapy. Even when it worked, the collateral damage was ...

Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the Gleevec pills, ...

Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...